Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyaluronate/chondroitin sulfate added to early mitomycin C after resection for low-risk non-muscle-invasive bladder cancer
2016-003813-92Phase 4Terminated
- Sponsor
- IBSA Group
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Ialuril and mitomycin c in non-muscle-invasive bladder cancer (NMIBC) and bladder cancer (2 arms), sponsored by IBSA Group. Primary endpoint: Absence of relapse at 24 months. Started Feb 2018; status: terminated.
02
Drugs
Ialurilmitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)bladder cancer
Beyond the preview
Go deeper on 2016-003813-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003813-92.